889858-12-2

tert-Butyl 4-Bromo-2-fluorobenzoate is an intermediate of enzalutamide (M199800). Enzalutamide is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.

[1] Patent: WO2016/102482, 2016, A1. Location in patent: Page/Page column 114
[2] Patent: US9242996, 2016, B2. Location in patent: Page/Page column 248; 251
[3] Patent: WO2016/97004, 2016, A1. Location in patent: Page/Page column 108